Novo Nordisk: The Management of Obesity for Appropriate Individuals: Questions, Answers and Resources

Recently, there has been significant interest in anti-obesity medications (AOMs) from the general public, employers, and access stakeholders. In an effort to provide decision-makers like you with information you may need when considering a weight-management approach for your employees or members, we have created these sample Q&As. The topics covered include:

  • Part 1: Impact of Weight Loss
  • Part 2: AOMs for the Treatment of Obesity or Overweight
    • Section 1: Your Population and AOMs
    • Section 2: The Evolution of AOM Coverage
    • Section 3: Integrating AOMs Into Your Organization’s Weight-Management Approach

Obesity and associated comorbidities are a prevalent and costly chronic condition that can impact the health of your employees and your organization. Novo Nordisk recognizes the challenges in the workplace created by obesity and aims to help employers understand the value of chronic weight management

Latest Posts
Partner News
Aon GLP-1 Study: Reduced Rise in Medical Costs for Users, Pronounced Benefits for Women
In May 2025, Aon released the first phase of a US study of GLP-1 medications ...
Read More
Partner News
Novo Nordisk – Time to Take on Obesity in Your Organization
As an employer, take action to help control healthcare costs and improve employee wellness. Obesity ...
Read More
Partner News
nudge: 2026 Global financial wellbeing calendar – Roadmap for supporting every employee everywhere
Financial pressure is reshaping daily life. Globally, people are having to make tough choices: 44% have cut non-essential ...
Read More
Follow SVEF
Scroll to Top

Join the Mailing List

Contact the Team

This field is for validation purposes and should be left unchanged.
Name(Required)